effectiveness of a mobile scalable device to detect the impairing effects of different drugs. The primary purpose of the data collected is to determine eligibility in a driving simulation study and to verify the effectiveness of the experimental manipulations. The findings will provide valuable information concerning the utility and effectiveness of mobile, smartphone/tablet-based neurocognitive assessment that can provide a multifactorial evaluation of cognitive functioning associated with impaired driving.

OMB approval is requested for 18 months. There are no costs to respondents other than their time. The total annualized burden hours are 58.

### ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Form name</th>
<th>Type of respondent</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden per respondent (in hours)</th>
<th>Per annual hour burden</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phone Screening</td>
<td>Adults</td>
<td>100</td>
<td>1</td>
<td>10/60</td>
<td>17</td>
</tr>
<tr>
<td>Driving Survey</td>
<td>Adults</td>
<td>72</td>
<td>1</td>
<td>15/60</td>
<td>18</td>
</tr>
<tr>
<td>Realism Survey</td>
<td>Adults</td>
<td>72</td>
<td>1</td>
<td>3/60</td>
<td>4</td>
</tr>
<tr>
<td>Sleep and Intake Questionnaire</td>
<td>Adults</td>
<td>72</td>
<td>2</td>
<td>3/60</td>
<td>7</td>
</tr>
<tr>
<td>Stanford Sleepiness Scale</td>
<td>Adults</td>
<td>72</td>
<td>6</td>
<td>1/60</td>
<td>7</td>
</tr>
<tr>
<td>Wellness Survey</td>
<td>Adults</td>
<td>72</td>
<td>2</td>
<td>2/60</td>
<td>5</td>
</tr>
</tbody>
</table>


Dated: March 25, 2013.

Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.

(Billing Code 4140-01-P)

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

**Center For Scientific Review; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel on Rheumatology, Dermatology and Osteoclast Biology.

Date: April 30, 2013.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call)

Contact Person: Aruna K Behera, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4211, MSC 7814, Bethesda, MD 20892, 301–435–6809, beheraak@csr.nih.gov

(Department of Health and Human Services)

Dated: March 25, 2013.

Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.

(Billing Code 4140-01-P)

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

**Center for Scientific Review; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel on Rheumatology, Dermatology and Osteoclast Biology.

Date: April 30, 2013.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Aruna K Behera, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4211, MSC 7814, Bethesda, MD 20892, 301–435–6809, beheraak@csr.nih.gov

(Department of Health and Human Services)

Dated: March 25, 2013.

Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.

(Billing Code 4140-01-P)
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDDK.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel Tumor Immunology.

Date: June 26–27, 2013.

Time: 6:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Express, 1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Robert Bird, Ph.D., Chief Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8113, Bethesda, MD 20892–1818, birdr@mail.nih.gov

Closed Meeting